- Antidiarrheal agents
- Antiulcer agents
Gastrointestinal Therapeutics Market size was valued at USD 52.8 billion in 2022, growing at a CAGR of 6.9% from 2023 to 2029. The global market provides a detailed overview of the Gastrointestinal Therapeutics market, and that can be segmented by drug, by mode of administration, by application, and by Distribution channel. By drug, the Gastrointestinal Therapeutics market has been segmented into antacids, Laxatives, Antidiarrheal agents, Antiemetics, Antiulcer agents, and Others. The Laxatives segment is likely to be the significant growing segment in drugs. Based on the Mode of administration, the Gastrointestinal Therapeutics market is segmented into Oral, Intravenous, and Others. Among these, the Intravenous segment is expected to have the fastest-growing market during the forecast period 2022-2028. The considerable share is expected to be an outcome of the advantages related to IV products. It can also be due to the high price of IV products compared to oral care products. Based on the application, the Gastrointestinal Therapeutics market is segmented into Gastroenteritis, Gastrointestinal Bleeding, Irritable Bowel Syndrome, and Peptic Ulcer. The Gastroenteritis Gastrointestinal Bleeding segment is expected to have a significant share in 2021. The rise of this segment is mainly because it offers an extensive range of applications for which gastrointestinal medicines have been used steadily over the prior years. Recurrent drug launches is also accountable for increased scope for development. Based on the Distribution channel, the Gastrointestinal Therapeutics market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The Retail Pharmacies segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the convenience and high affordability of retail stores. As the number of prescription drugs being compensated grows, it inspires patients to buy medicines from retail pharmacies. Retail pharmacists also endorse drug alternatives that avoid severe drug interactions.
In February 2021, in the United States, Lansoprazole delayed-release orally disintegrating tablets were launched by Dr. Reddy's Laboratories. In March 2020, Sebela Pharmaceuticals got approval from FDA for Pizensy (lactitol) for curing chronic idiopathic constipation (CIC) in adults.
Fastest Growing Market
The growing incidence of gastrointestinal diseases is anticipated to propel the market growth over the forecast years. Moreover, the increasing clinical trials with promising results and increasing expenditure on healthcare are burgeoning the market growth over the forecast years.
The gastrointestinal therapeutics market size was valued at USD 52.8 billion in 2022
The gastrointestinal therapeutics market key players are: Abbott Laboratories (US) Allergan (Ireland) AstraZeneca plc (UK) GlaxoSmithKline Plc (UK) Takeda Pharmaceutical Company Limited (Japan) Pfizer Inc. (US) Bayer AG (Germany) Bausch Health (Canada) Merck & Co., Inc. (US) AbbVie Inc. (US)
The gastrointestinal therapeutics market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.